AbbVie Inc.

Equities

Market Closed - Nyse Other stock markets 04:00:03 2026-03-12 pm EDT			After hours 07:00:10 pm
225.37 ^USD	-1.01%		224.74	-0.28%

Mar. 10	AbbVie Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 11:20 AM
Mar. 09	AbbVie says CEO Robert Michael's 2025 total compensation was $32.5 million - SEC filing	RE

Published on 02/04/2026 at 11:50 am EST - Modified on 02/25/2026 at 03:57 am EST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, and thank you for standing by. Welcome to the AbbVie Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] Today's call

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Mar. 10	AbbVie Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 11:20 AM
Mar. 09	AbbVie says CEO Robert Michael's 2025 total compensation was $32.5 million - SEC filing	RE
Mar. 09	AbbVie Announces Positive Topline Results From A Phase 1 Multiple Ascending Dose Study of ABBV-295	CI
Mar. 09	Global drugmakers rush to boost US presence as tariff threat looms	RE
Mar. 09	Global markets live: Live Nation, Eli Lilly, Amazon, Microsoft, ABB…
Mar. 09	AbbVie's Study of Weight-Loss Drug Outperforms Placebo	MT
Mar. 09	Gubra's partner AbbVie reports positive phase 1 results for ABBV-295	RE
Mar. 09	Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study	RE
Mar. 05	Illumina, Inc. and Nashville Biosciences, LLC Announce New Proteomics Data Offering and Expansion of Alliance for Genomic Discovery Dataset	CI
Mar. 05	Evercore ISI Adjusts AbbVie Price Target to $233 From $228, Maintains Outperform Rating	MT
Mar. 04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
Mar. 04	When Talk of Talks Moves Markets
Mar. 04	Allergan aesthetics highlights medical weight loss (MWL) data and the changing profile of patients	RE
Mar. 03	AbbVie Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 11:10 AM
Mar. 02	AbbVie's Subcutaneous Skyrizi Meets Co-Primary Efficacy Endpoints in Phase 3 Crohn's Trial	MT